CYP26A1 and acute myeloid leukemia: Given our previous results regarding ATRA response and previous studies highlighting the pro‐differentiation effects on AML of inhibiting CYP26, a key player in retinol metabolism,8 we next combined ATRA and the CYP26 inhibitor talarozole in control and HRH1‐KD HL60 cells.